Plasma Cell Tumors
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors (NCT04665076) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-10-22 |
Track Plasma Cell Tumors automatically
Every clearance here is in the API, with alerts when new ones post.